AdvanCell raised a $315 million Series D to advance a lead radiopharmaceutical candidate toward late-stage development and to expand US manufacturing capacity. The financing is framed as a response to a capacity constraint that has limited throughput across the radiopharmaceutical value chain. The round positions AdvanCell as a Pluvicto challenger builder in prostate cancer, with plans to push its program forward while scaling production to support broader trial activity and potential commercial demand. For the radiopharma sector, the size and purpose of the funding highlight continued investor confidence in pipeline expansion—paired with an emphasis on manufacturing as a key gating factor.